New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court

Share Article

In response to this and other recent Zofran lawsuit filings, Bernstein Liebhard LLP has launched an investigation into allegations that the anti-nausea medication may cause birth defects when used during the first trimester of pregnancy.

Free Case Review
This is at least the third Zofran lawsuit filed over birth defect allegations since last month, all of which put forth very similar claims regarding the purported link between this medication and serious congenital abnormalities.

A new Zofran lawsuit (http://www.zofranlawsuit2015.com/) has been filed in California Superior Court on behalf of a child who was allegedly born with a serious heart birth defect after his mother was prescribed the anti-nausea medication during the first trimester of pregnancy. According to the March 6th filing in Alameda Superior Court, the baby’s mother was prescribed Zofran off-label to alleviate nausea and vomiting that she experienced in the early months of her pregnancy. The little boy, who was born in 2010, was diagnosed with supraventricular tachycardia, which the complaint alleges was the direct and proximate result of prenatal exposure to Zofran. (Case No. RG15761042)

“This is at least the third Zofran lawsuit filed over birth defect allegations since last month, all of which put forth very similar claims regarding the purported link between this medication and serious congenital abnormalities. In addition, the lawsuits allege that GlaxoSmithKline improperly marketed Zofran as a remedy for pregnancy-related nausea and vomiting, which is an indication for which it has not received regulatory approval.* Our Firm has since launched its own investigation into this medication, and will be monitoring developments pertaining to the Zofran litigation very closely” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently reviewing claims on behalf of families whose child was allegedly born with a serious birth defect due to pre-natal exposure to Zofran.

Zofran Birth Defect Allegations
In addition to the Zofran lawsuit pending in California, court documents indicate that a similar birth defect claim was filed on February 12th in the U.S. District Court, Eastern District of Pennsylvania, by a woman who alleges her use of Zofran during both of her pregnancies in 2004 and 2006 caused her two children to be born with serious heart abnormalities. (Case 2:15-cv-00709-PD). Just days later, on February 16th, a second Zofran complaint was filed in the U.S. District Court, District of Massachusetts, by a woman who alleges her baby daughter was born with a number of serious congenital abnormalities, including heart defects, after she was prescribed Zofran to treat nausea and vomiting during her pregnancy. (Case 1:15-cv-10429)

Court records indicate that all of the lawsuits cite much of the same evidence to support their allegations, including studies that suggest prenatal exposure to Zofran during the first trimester of pregnancy may be associated with heart abnormalities, orofacial defects and other serious malformations. Among other things, the complaints allege that since 1992, GlaxoSmithKline has received more than 200 reports of birth defects in children who were exposed to Zofran during early pregnancy. Plaintiffs also accuse the drug company of improperly marketing Zofran to treat pregnancy-related nausea and vomiting, and note that that Glaxo previously agreed to pay $3 billion to settle charges with the U.S. Department of Justice regarding the marketing of a number of medications. Among other things, the 2012 accord resolved claims that Glaxo had improperly marketed Zofran as a treatment for morning sickness.

Children who allegedly suffered serious birth defects due to their mother’s use of Zofran during the first trimester of pregnancy may be eligible to pursue a Zofran lawsuit against GlaxoSmithKline. To find out more about available legal options, please visit Bernstein Liebhard LLP’s website, or call the Firm directly at 800-511-5092.

*accessdata.fda.gov/drugsatfda_docs/label/2014/020007s046lbl.pdf, FDA, September 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.zofranlawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website